Literature DB >> 2545406

Effects of etodolac on human chondrocytes cultivated in three dimensional culture.

Y Henrotin1, C Bassleer, J Y Reginster, P Franchimont.   

Abstract

Human chondrocytes in three-dimensional culture were incubated for up to 20 days in the presence of etodolac, a nonsteroidal anti-inflammatory drug which penetrates readily into the synovial fluid. Even at an etodolac concentration of 80 micrograms/ml, DNA synthesis, proteoglycan synthesis, and type-II collagen synthesis were unchanged. Collagenase production was also unaffected by etodolac (60 micrograms/ml). In contrast, prostaglandin E2 production was reduced by 84% in the presence of 60 micrograms/ml of etodolac. The 80 micrograms/ml concentration is 5 times that found in the serum of subjects treated with 200 mg of etodolac twice a day for 6 days, and 33 times the concentration in synovial fluid of arthritic patients treated with etodolac 200 mg twice a day for 7 days. These in vitro results indicate that anti-inflammatory levels of etodolac may not damage articular cartilage in vivo.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2545406     DOI: 10.1007/BF02214108

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  9 in total

1.  A rapid and reproducible assay for collagenase using [1-14C]acetylated collagen.

Authors:  T E Cawston; A J Barrett
Journal:  Anal Biochem       Date:  1979-11-01       Impact factor: 3.365

2.  The pharmacokinetics of etodolac in serum and synovial fluid of patients with arthritis.

Authors:  M Kraml; D R Hicks; M McKean; J Panagides; D Furst; J Furst
Journal:  Clin Pharmacol Ther       Date:  1988-05       Impact factor: 6.875

3.  Proteoglycans synthesized by human chondrocytes cultivated in clusters.

Authors:  C Bassleer; P Gysen; R Bassleer; P Franchimont
Journal:  Am J Med       Date:  1987-11-20       Impact factor: 4.965

4.  Effects of peptidic glycosaminoglycans complex on human chondrocytes cultivated in three dimensions.

Authors:  C Bassleer; P Gysen; R Bassleer; P Franchimont
Journal:  Biochem Pharmacol       Date:  1988-05-15       Impact factor: 5.858

5.  Nonsteroidal antiinflammatory drugs in treatment of osteoarthritis.

Authors:  K D Brandt; S Slowman-Kovacs
Journal:  Clin Orthop Relat Res       Date:  1986-12       Impact factor: 4.176

6.  Radioimmunoassay of proteoglycans.

Authors:  P Gysen; P Franchimont
Journal:  J Immunoassay       Date:  1984

7.  Influence of nonsteroidal anti-inflammatory agents on lapine articular chondrocyte growth in vitro.

Authors:  C J Kirkpatrick; W Mohr; A Mildfeuer; O Haferkamp
Journal:  Z Rheumatol       Date:  1983 Mar-Apr       Impact factor: 1.372

8.  Human chondrocytes in tridimensional culture.

Authors:  C Bassleer; P Gysen; J M Foidart; R Bassleer; P Franchimont
Journal:  In Vitro Cell Dev Biol       Date:  1986-03

9.  Effects of nonsteroidal anti-inflammatory drugs on chondrocyte metabolism in vitro and in vivo.

Authors:  K D Brandt
Journal:  Am J Med       Date:  1987-11-20       Impact factor: 4.965

  9 in total
  5 in total

Review 1.  Etodolac. A reappraisal of its pharmacology and therapeutic use in rheumatic diseases and pain states.

Authors:  J A Balfour; M M Buckley
Journal:  Drugs       Date:  1991-08       Impact factor: 9.546

Review 2.  Etodolac: efficacy in osteoarthritis and effects on chondrocyte function.

Authors:  P A Bacon
Journal:  Rheumatol Int       Date:  1990       Impact factor: 2.631

3.  International experience with etodolac therapy for rheumatoid arthritis: an interim report of comparative efficacy.

Authors:  D Briancon
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

4.  Recent clinical experience with etodolac in the treatment of osteoarthritis of the knee.

Authors:  P N Platt
Journal:  Clin Rheumatol       Date:  1989-03       Impact factor: 2.980

5.  Comparison of Clinical Effectiveness and Safety of Newer Nonsteroidal Anti-inflammatory Drugs in Patients of Osteoarthritis of Knee Joint: A Randomized, Prospective, Open-label Parallel-group Study.

Authors:  Yashika Garg; Jatinder Singh; H S Sohal; Rajeshwari Gore; Arun Kumar
Journal:  Indian J Pharmacol       Date:  2017 Sep-Oct       Impact factor: 1.200

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.